The primary objectives of the study are to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab + docetaxel combination therapy in solid tumors.
After completion of the Safety Run-in Cohort 1, Phase 2 Cohort 1 will occur as follows:
Phase 2 Cohort 1: a cohort of participants with solid tumors (metastatic non-small cell lung cancer (mNSCLC) (Phase 2 Cohort 1a), metastatic urothelial cancer (mUC) (Phase 2 Cohort 1b), and metastatic small cell lung cancer (mSCLC) (Phase 2 Cohort 1c).
Inclusion/Exclusions: ECOG 0-2. Measurable disease by RECIST, Stable CNS allowed. No prior tx w/ CD47-or signal reg protein alpha targeting tx. No active HIV, HBV or HCV.